About this Series

Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed leukemia in older Americans. Diagnosis often occurs when patients are asymptomatic, and doctors often must decide between initiating treatment and adopting a wait-and-see approach.

In this three-part series, hematologists at MD Anderson discuss factors for deciding when to begin treatment, how to characterize patients' disease as low or high risk, and tailoring therapies on the basis of patients' risk profile. The hematologists explore recent developments in treatment options beyond chemotherapy, including monoclonal antibodies, targeted therapies, and small-molecule inhibitors.

Show More

Who's Who
More on Chronic Lymphocytic Leukemia